000294570 001__ 294570
000294570 005__ 20241119182558.0
000294570 0247_ $$2doi$$a10.3389/fimmu.2024.1471198
000294570 0247_ $$2pmid$$apmid:39530098
000294570 0247_ $$2pmc$$apmc:PMC11550951
000294570 037__ $$aDKFZ-2024-02345
000294570 041__ $$aEnglish
000294570 082__ $$a610
000294570 1001_ $$aLu, Yangbai-$$b0
000294570 245__ $$aCuproptosis-related lncRNAs emerge as a novel signature for predicting prognosis in prostate carcinoma and functional experimental validation.
000294570 260__ $$aLausanne$$bFrontiers Media$$c2024
000294570 3367_ $$2DRIVER$$aarticle
000294570 3367_ $$2DataCite$$aOutput Types/Journal article
000294570 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1732012964_4248
000294570 3367_ $$2BibTeX$$aARTICLE
000294570 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294570 3367_ $$00$$2EndNote$$aJournal Article
000294570 500__ $$a#EA:C070#
000294570 520__ $$aProstate cancer (PCa) is one of the most common malignancies of the urinary system. Cuproptosis, a newly discovered form of cell death. The relationship between cuproptosis-related long non-coding RNAs (ClncRNAs) related to PCa and prognosis remains unclear. This study aimed to explore the clinical significance of novel ClncRNAs in the prognostic assessment of PCa.ClncRNAs and differentially expressed mRNAs linked to these ClncRNAs were identified using Pearson's correlation and differential expression analyses. A prognostic signature (risk score) comprising three ClncRNAs was established based on multivariable Cox regression analysis. The predictive performance of this ClncRNAs signature was validated using receiver operating characteristic curves and nomograms. Finally, further in vitro cell experiments were conducted for validation, including quantitative polymerase chain reaction (qPCR), western blot (WB), cell proliferation assays, cell migration assays, cell invasion assays, apoptosis, and cell cycle analysis.We constructed a prognostic signature of ClncRNAs for PCa comprising three key differentially expressed ClncRNAs(AC010896-1, AC016394-2, and SNHG9). Multivariable Cox regression analysis indicated that clinical staging and risk scores of the ClncRNAs signature were independent prognostic factors for PCa. Compared to other clinical features, the ClncRNAs signature exhibited higher diagnostic efficiency and performed well in predicting the 1-, 3-, and 5-year progression-free intervals (PFIs) for PCa. Notably, in terms of immune activity, PCa patients with high-risk scores exhibited higher tumor mutational burden (TMB) levels, while their Tumor Immune Dysfunction and Exclusion (TIDE) scores were lower than those of PCa patients with low-risk scores. Additionally, in vitro cellular functional experiments, we knocked down SNHG9 that is the most significantly differentially expressed ClncRNA among the three key ClncRNAs. SNHG9 knockdown resulted in a significant increase in G1 phase cells and a decrease in S and G2 phases, indicating inhibition of DNA synthesis and cell cycle progression. Colony formation assays showed reduced clonogenic ability, with fewer and smaller colonies. Western blot analysis revealed the upregulation of the key cuproptosis-related mRNAs FDX1 and DLST. These findings suggested that SNHG9 promotes PCa cell proliferation, migration, and invasion.Building on the three ClncRNAs, we identified a novel prognostic signature of PCa. The ClncRNA SNHG9 can promote PCa cell proliferation, migration, and invasion.
000294570 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000294570 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294570 650_7 $$2Other$$aSNHG9
000294570 650_7 $$2Other$$acuproptosis
000294570 650_7 $$2Other$$alncRNAs
000294570 650_7 $$2Other$$aprognosis signature
000294570 650_7 $$2Other$$aprostate carcinoma
000294570 650_7 $$2NLM Chemicals$$aRNA, Long Noncoding
000294570 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000294570 650_2 $$2MeSH$$aHumans
000294570 650_2 $$2MeSH$$aRNA, Long Noncoding: genetics
000294570 650_2 $$2MeSH$$aMale
000294570 650_2 $$2MeSH$$aProstatic Neoplasms: genetics
000294570 650_2 $$2MeSH$$aProstatic Neoplasms: pathology
000294570 650_2 $$2MeSH$$aPrognosis
000294570 650_2 $$2MeSH$$aBiomarkers, Tumor: genetics
000294570 650_2 $$2MeSH$$aGene Expression Regulation, Neoplastic
000294570 650_2 $$2MeSH$$aCell Line, Tumor
000294570 650_2 $$2MeSH$$aCell Proliferation: genetics
000294570 650_2 $$2MeSH$$aAged
000294570 650_2 $$2MeSH$$aGene Expression Profiling
000294570 650_2 $$2MeSH$$aMiddle Aged
000294570 650_2 $$2MeSH$$aCell Movement: genetics
000294570 650_2 $$2MeSH$$aTranscriptome
000294570 650_2 $$2MeSH$$aNomograms
000294570 650_2 $$2MeSH$$aApoptosis: genetics
000294570 7001_ $$aWu, Jinfeng-$$b1
000294570 7001_ $$0P:(DE-He78)a92f91afa83da73641a4f3abec1d3c6d$$aLi, Xianzhe$$b2$$eFirst author$$udkfz
000294570 7001_ $$aLeng, Qu-$$b3
000294570 7001_ $$aTan, Jian-$$b4
000294570 7001_ $$aHuang, Hongxing-$$b5
000294570 7001_ $$aZhong, Rui-$$b6
000294570 7001_ $$aChen, Zhenjie-$$b7
000294570 7001_ $$aZhang, Yongxin-$$b8
000294570 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2024.1471198$$gVol. 15, p. 1471198$$p1471198$$tFrontiers in immunology$$v15$$x1664-3224$$y2024
000294570 909CO $$ooai:inrepo02.dkfz.de:294570$$pVDB
000294570 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a92f91afa83da73641a4f3abec1d3c6d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000294570 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000294570 9141_ $$y2024
000294570 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2022$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T10:28:02Z
000294570 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T10:28:02Z
000294570 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T10:28:02Z
000294570 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-11T10:28:02Z
000294570 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2022$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000294570 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000294570 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000294570 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000294570 980__ $$ajournal
000294570 980__ $$aVDB
000294570 980__ $$aI:(DE-He78)C070-20160331
000294570 980__ $$aUNRESTRICTED